Formulation and statistical optimization of a novel crosslinked polymeric anti-tuberculosis drug delivery system

Journal of Pharmaceutical Sciences

Volumn 97, Issue 6, 2008, Pages 2176-2207

  Toit, Lisa Claire Du ^a   Pillay, Viness ^a   Danckwerts, Michael Paul ^a   Penny, Clement ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Box behnken experimental design; Crosslinking; Mechanical properties; Poly(methacrylic acid coethylacrylate) copolymer; Polyelectrolytes; Response surface methodology; Salting out; Site specific delivery; Targeted drug delivery; Tuberculosis

Indexed keywords

CITRIC ACID; ELECTROLYTE; ISONIAZID; PLASTICIZER; POLYMER; RIFAMPICIN; RIFANAH; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ZINC; ZINC SULFATE; CROSS LINKING REAGENT; DRUG CARRIER; ETHYL CITRATE;

ARTICLE; BIVARIATE ANALYSIS; CONCENTRATION (PARAMETERS); CROSS LINKING; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; GASTROINTESTINAL TRACT; IN VITRO STUDY; INOTROPISM; MEDICAL RESEARCH; METHODOLOGY; REACTION TIME; REGRESSION ANALYSIS; SIMULATION; SMALL INTESTINE; STOMACH PH; TEMPERATURE; ULTRAVIOLET SPECTROPHOTOMETRY; CHEMICAL MODEL; CHEMISTRY; DRUG COMBINATION; KINETICS; ORAL DRUG ADMINISTRATION; PH; PHARMACEUTICS; SOLUBILITY; STATISTICAL MODEL; STOMACH JUICE; SURFACE PROPERTY;

ADMINISTRATION, ORAL; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; CITRATES; CROSS-LINKING REAGENTS; DRUG CARRIERS; DRUG COMBINATIONS; GASTRIC JUICE; HYDROGEN-ION CONCENTRATION; ISONIAZID; KINETICS; LEAST-SQUARES ANALYSIS; MODELS, CHEMICAL; MODELS, STATISTICAL; PLASTICIZERS; POLYMERS; RIFAMPIN; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; ZINC SULFATE;

EID: 49249094762     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21159     Document Type: Article

References (74)

1. Blomberg B, Fourie B. 2003. Fixed dose combination drugs for tuberculosis: Application in standardised treatment regimens. Drugs 63:535-553.
2. Panchagnula R, Agrawal S. 2004. Biopharmaceutic and pharmacokinetic aspects of variable bioavail-ability of rifampicin. Int J Pharm 271:1-4.
3. Blomberg B, Spinaci S, Fourie B, Laing R. 2001. The rationale for recommending ñxed-dose combination tablets for treatment of tuberculosis. Bull WHO 79:61-79.
4. Agrawal S, Singh I, Jit Kaur K, Bhade S, Lai Kaul C, Panchagnula R. 2004a. Bioequivalence trials of rifampicin containing formulations: Extrinsic and intrinsic factors in the absorption of rifampicin. Pharm Res 50:317-327.
5. Laing R, Fourie B, Ellard G, Sesay M, Spinaci S, Blomberg B, Bryant D. 1999. Fixed-dose combination tablets for the treatment of tuberculosis. Report of an informal meeting held in Geneva, Tuesday, 27 April 1999. World Health Organization, Geneva, WHO/CDS/CPC/TB/99.267.
6. Agrawal S, Ashokraj Y, Bharatam PV, Pillai O, Panchagnula R. 2004b. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur J Pharm Sci 22:127-144.
7. Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R. 2004c. Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from fixed dose combination formulations. Int J Tuberc Lung Dis 9(11): 1275-1280
8. Agrawal S, Panchagnula R. 2004. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. Int J Pharm 287:97-112.
9. Chen Y-J. 2000. The solubility enhancement and the stability assessment of rifampicin, isoniazid and pyrazinamide in aqueous media. Master of Science Thesis, South Africa, Rhodes University.
10. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Vora MJ. 2001. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm 228:53-67.
11. Singh S, Mariappan TT, Sharda N, Chakraborti AK. 2000a. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm Pharmacol Comm 6:405-410.
12. Singh S, Mariappan TT, Sharda N, Singh B. 2000b. Degradation of rifampicin, isoniazid and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions. Pharm Pharmacol Comm 6:491-494.
13. Singh S, Mariappan TT, Shankar R, Sarda N, Singh B. 2001. A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm 228:5-17.
14. Mohan B, Sharda N, Singh S. 2003. Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin. J Pharm Biomed Anal 31:607-612.
15. Mariappan TT, Jindal KC, Singh S. 2004. Overestimation of rifampicin during colorimetric analysis of anti-tuberculosis products containing isoniazid due to formation of isonicotinyl hydrazone. J Pharmaceut Biomed Anal 36:905-908.
16. Prasad B, Bhutani H, Singh S. 2006. Study of the interaction between rifapentine and isoniazid under acid conditions. J Pharm Biomed Anal 41:1438-1441.
17. Sankar R, Sharda N, Singh S. 2003. Behaviour of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3. Drug Dev Ind Pharm 29:733-738.
18. Acocella G, Luisetti M, Grassi GG, Peona V, Pozzi E, Grassi C. 1993. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed triple-formulation) in termittent antituber-culosis chemotherapy. Monaldi Arch Chest Dis 48: 205-209.
19. Gurumurthy P, Ramachandran G, Vijayalakshmi S, Kumar AK, Venkatesan P, Chandrasekaran V, Vjayasekar V. 1999. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: Comparison of plasma and urine kinetics. Int J Tuberc Lung Dis 3:119-125.
20. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. 2004d. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 276:41-49.
21. Agrawal S, Panchagnula R. 2005. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage Forms. Biopharm Drug Dispos 26:321-334.
22. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. 1992. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 36:548-551.
23. Immanuel C, Gurumurthy P, Ramachandran G, Venkatesan P, Chandrasekaran V, Prabhakar R. 2003. Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs. Indian J Med Res 118:109-114.
24. Mariappan TT, Singh S. 2003. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat. Int J Tuberc Lung Dis 7:797-803.
25. Long MW, Snider DR, Farer LS. 1979. US Public Health service cooperative trial of three RIF-INH regimens in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 119:879-894.
26. Seifart HI, Parkin DP, Donald PR. 1991. Stability of isoniazid, rifampicin and pyrazinamide in suspensions used for the treatment of tuberculosis in children. Pediatr Infect Dis 10:827-831.
27. Mariappan TT, Jindal KC, Singh S. 2004. Over-estimation of rifampicin during colorimetric analysis of anti-tuberculosis products containing isoniazid due to formation of isonicotinyl hydrazone. J Pharmaceut Biomed Anal 36:905-908.
28. Butani H, Singh S, Jindal KC. 2005. Drug-drug interaction studies on first-line anti-tuberculosis drugs. Pharm Dev Technol 10:517-524.
29. Garg SK, Dhand R, Malik SK, Kalra S, Gupta PH, Jha VK, Lal R. 1988. Single dose kinetics of rifampicin and isoniazid in well-nourished and malnourished patients of tuberculosis. Int J Clin Pharmacol Ther Toxicol 26:417-420.
30. Llorens J, Serrano RJ, Sanchez R. 1978. Pharmacodynamic interference between rifampicin and isoniazid. Chemotherapy 24:97-103.
31. Skakun NP, Tabachuk OE. 1992. The comparative action of isoniazid, rifampicin and ethambutol on liver function. Eksp Klin Farmakol 55:45-47.
32. Yew WW. 2002. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf 25:111-133.
33. Lippold BC. 1990. In: Gundert-Remy U, Moller H, editors. Oral controlled products: Therapeutic and biopharmaceutic assessment. Stuggart: Wissen-schaftlice Verlagsgesellschaft. pp. 39-57.
34. Follinier N, Doelker E, Cole ET. 1994. Evaluation of hot-melt-extrusion as new technique for the production of polymer based pellets for sustained release capsules containing high loadings of freely soluble drugs. Drug Dev Ind Pharm 20:1323-1339.
35. Ghebre-Sellassie I, editor. 1994. Multipaticulate oral drug delivery. New York, NY: Marcel Dekker, Inc. pp. 333-355.
36. Pillay V, Fassihi R. 1999. In vitro release modulation from crosslinked pellets for site-specific drug delivery to the gastrointestinal tract: I. Comparison of pH-responsive drug release and associated kinetics. J Contr Rel 59:229-242.
37. Schmidt C, Bodmeier R. 2001. A multiparticulate drug-delivery system based on pellets incorporated into congealable polyethylene glycol carrier materials. Int J Pharm 216:9-16.
38. Hosny E, Al-Shora H, Elmazar M. 2002. Oral delivery of insulin from enteric-coated capsules containing salicylate: Effect on relative hypoglycemia of diabetic beagle dogs. Int J Pharm 237:71-76.
39. Guo HX, Heinamaki J, Yliruusi J. 2002. Diffusion of a freely water-soluble drug in aqueous enteric-coated pellets. AAPS PharmSciTech 3: article 16.
40. Bianchini R, Resciniti M, Vecchio C. 1991. Technology evaluation of aqueous enteric coating systems with and without insoluble additives. Drug Dev Ind Pharm 17:1779-1794.
41. Allain C, Salome L. 1990. Gelation of semidilute polymer solutions by ion-complexation: Critical behavior of the rheological properties versus cross-linking. Macromolecules 23:981-987.
42. Cohen S, Andrianov AK, Wheatley M, Allcock HR, Langer RS. 1996. Gas-filled polymeric microbubbles for ultrasound imaging. United States Patent No. 5,487,390.
43. Plumridge TH, Steele G, Waigh RD. 2000. Geometry-based simulation of the hydration of small molecules. Phys Chem Comm 3:36.
44. Sastry SV, Reddy IK, Khan MA. 1997. Atenolol gastrointestinal therapeutic system: Optimization of formulation variables using response surface methodology. J Contr Rel 45:121-130.
45. Nielson LE, Landel RF. 1993. Mechanical properties of polymers and composites. Vol. 2, New York: Marcel Dekker. pp. 15-22.
46. McGinity JW, editor. 1996. Aqueous polymeric coatings for pharmaceutical dosage forms. New York: Marcel Dekker. pp. 62-75. 108.
47. Myers RH, Montgomery DC. 1995. Response surface methodology: Process and product optimization using designed experiments. New York: Wiley-Interscience Publication.
48. Singh Rekhi G, Nellore RV, Hussain AS, Tillman LG, Malinowski HJ, Augsburger LL. 1999. Identification of critical formulation and processing variables for metoprolol tartrate extended-release (ER) matrix tablets. J Contr Rel 59:327-342.
49. Fassihi AR. 1988. Consolidation behaviour of polymeric substances in non-disintegrating solid matrices. Int J Pharm 44:249-256.
50. Bodmeier R, Paeratakul O. 1994. Mechanical properties of dry and wet cellulosic and acrylic films prepared from aqueous colloidal polymer dispersions used in the coating of solid dosage forms. Pharm Res 11:882-888.
51. du Toit LC, Pillay V, Danckwerts MP. 2006. Application of synergism and variation in ionic compatibilities within a hydrophilic polymeric sodium starch glycolate-κ-carrageenan combination: Textural profiling of the suspension behavior. J Bioact Compat Pol 21:107-122.
52. Shah Y, Khanna S, Jindal K, Dighe VS. 1992. High performance liquid chromatographic analysis. Drug Dev Ind Pharm 18:1589-1596.
53. Prabakaran D, Singh P, Jaganathan KS, Vyas SP. 2004. Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs. J Contr Rel 95:239-248.
54. Buniva G, Pagani V, Carozzi A. 1983. Bioavailability of rifampicin capsules. Int J Clin Pharmacol Ther Toxicol 21:404-409.
55. Goicoechea HC, Olivieri AC. 1999. Simultaneous determination of rifampicin, isoniazid and pyrazinamide in tablet preparations by multivariate spectrophotometric calibration. J Pharm Biomed Anal 20:681-686.
56. Mehta KA, Kislalioglu MS, Phuapradit W, Malick AW, Shah NH. 2000. Effect of formulation and process variables on porosity parameters and release rates from a multi unit erosion matrix of a poorly soluble drug. J Contr Rel 63:201-211.
57. Netz DJA, Sepulveda P, Pandolfelli VC, Spadaro ACC, Alencastre JB, Bentley MVLB, Marchetti JM. 2001. Potential use of gelcasting hydroxyapatite porous ceramic as an implantable drug delivery system. Int J Pharm 213:117-125.
58. Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. 2003. Physicochemical properties to determine the buoyancy of hollow microspheres (microballoons) prepared by the emulsion solvent diffusion method. Eur J Pharm Biopharm 55:297-304.
59. US Pharmacopeia XXV. 2001. Drug Release. Rockville, MD: United States Pharmacopeial Convention. 724.
60. Pillay V, Fassihi R. 1998. Evaluation and comparison of dissolution data derived from different modified release dosage forms: An alternative method. J Contr Rel 55:45-55.
61. Govender S, Pillay V, Chetty DJ, Essack SY, Dan-gor CM, Govender T. 2005. Optimisation and characterisation of bioadhesive controlled release tetracycline microspheres. Int J Pharm 306:24-40.
62. United States Pharmacopeia XXIV. 2000. Physical tests, Delayed Release (enteric coated) articles-General drug release standard. 1940-1947.
63. Florey K, editor. 1976. Analytical profiles of drug substances. Vol. 5 New York, San Francisco, London: Academic Press. pp. 470-500.
64. United States Pharmacopeia XXII. 1990. United States Pharmacopeial Convention, Rockville, MD: 729-730, 1227-1228.
65. Taha MO, Aiedah KM, Al-Hiari Y, Al-Khatib H. 2005. Synthesis of zinc-crosslinked thiolated alginic acid and their in vitro evaluation as potential enteric delivery system with folic acid as model drug. Pharmazie 60:736-742.
66. Badve SS, Sher P, Korde A, Pawar AP. 2007. Development of hollow/porous calcium pectinate beads for floating-pulsatile drug delivery. Eur J Pharm Biopharm 65:85-93.
67. Pillay V, Fassihi R. 1999. In vitro release modulation from crosslinked pellets for site-specific drug delivery to the gastrointestinal tract: I. Comparison of pH-responsive drug release and associated kinetics. J Contr Rel 59:229-242.
68. Swarbrick J, editor. 2004. Encyclopedia of Pharmaceutical Technology. 2nd ed. (update supplement), New York: Marcel Dekker. pp. 241-242.
69. Sriamornsak P. 1999. Effect of calcium concentration, hardening agent and drying condition on release characteristics of oral proteins from calcium pectinate gel beads. Eur J Pharm Sci 8:221-227.
70. Guo JH. 1993. Effects of plasticizers on water permeation and mechanical properties of cellulose acetate: Antiplasticization in slightly plasticized polymer film. Drug Dev Ind Pharm 19:1541-1555.
71. Saettone MF, Perini G, Rijli P, Rodriguez L, Cini M. 1995. Effect of different polymer-plasticizer combinations on 'in vitro' release of theophylline from coated pellets. Int J Pharm 126:83-88.
72. Sastry SV, Wilber W, Reddy IK, Khan MA. 1998. Aqueous-based polymeric dispersion: Preparation and characterization of cellulose acetate pseudolatex. Int J Pharm 165:175-189.
73. Sinko CM, Amidon GL. 1989. Plasticizer-induced changes in the mechanical rate of response of film coatings: Approach to quantitating plasticizer effectiveness. Int J Pharm 55:247-256.
74. Panchagnula R, Rungta S, Sancheti P, Agrawal S, Kaul CL. 2003. In vitro evaluation of food effect on the bioavailability of rifampicin from antituberculosis fixed dose combination formulations. Farmaco 58:1099-1103.